[ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
Correlation association between an ApoE4 genotype in patients with mild-moderate Alzheimer's disease and efficacy of neurotrophic (cerebrolysin) and cholinergic (exelon) therapy was studied in the groups of patients formed using case-control method. A 4-month treatment has shown that both types of therapy had a significant clinical effect, however clinical effect proved to be more higher and stable in patients treated with cerebrolysin. A number of responders in the cerebrolysin group was 1.7-fold higher comparing to that in the exelon group. Patients with the ApoE4(+) genotype did not differ in response to either drug but in those with genotype ApoE4(-) the number of responders was 3-fold higher in the group treated with cerebrolysin compared to the group given exelon. A follow-up estimation of cognitive impairment in ApoE4(-) patients revealed that long-term clinical effect of cerebrolysin treatment was 6.5 times higher than that of exelon.
Gavrilova
S I
SI
Kolykhalov
I V
IV
Korovaĭtseva
G I
GI
Zharikov
G A
GA
Kalyn
Ia B
IaB
Selezneva
N D
ND
D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D000596:Amino Acids / Q000627:therapeutic use*; D001057:Apolipoproteins E / Q000235:genetics*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000378:metabolism*; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D000068836:Rivastigmine
D000596:Amino Acids; D001057:Apolipoproteins E; D002800:Cholinesterase Inhibitors; D009414:Nerve Growth Factors; D018697:Nootropic Agents; D048448:Phenylcarbamates; C006952:cerebrolysin; D000068836:Rivastigmine